{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:13:38Z","timestamp":1794921218219,"version":"4.9.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.seizure.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:19:39Z","timestamp":1778451579000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["GLP-1 receptor agonists in people with epilepsy: A scoping review of clinical data, safety, and therapeutic implications"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-5120","authenticated-orcid":false,"given":"Lecio Figueira","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9381-8674","authenticated-orcid":false,"given":"Carlos Alberto Mantovani","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2026.05.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107878","article-title":"Cardiovascular disease risk, awareness, and treatment in people with epilepsy","volume":"117","author":"Terman","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"11","key":"10.1016\/j.seizure.2026.05.013_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-095195","article-title":"Is cardiovascular mortality among people with epilepsy increasing? A retrospective US population study","volume":"15","author":"Curtis","year":"2025","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0003","article-title":"Risk and outcomes of diabetes in patients with epilepsy","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.seizure.2026.05.013_bib0004","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"E Clin Med"},{"issue":"9","key":"10.1016\/j.seizure.2026.05.013_bib0005","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"Cao","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.seizure.2026.05.013_bib0006","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-Like Peptide-1: a focus on neurodegenerative diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Front Neurosci"},{"issue":"6","key":"10.1016\/j.seizure.2026.05.013_bib0007","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3892\/ijmm.2021.5052","article-title":"Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole-kindled mice","volume":"48","author":"Wang","year":"2021","journal-title":"Int J Mol Med"},{"issue":"20","key":"10.1016\/j.seizure.2026.05.013_bib0008","doi-asserted-by":"crossref","first-page":"e2071","DOI":"10.1212\/WNL.0000000000207222","article-title":"Association of long-term antiseizure medication use and incident type 2 diabetes mellitus","volume":"100","author":"Tseng","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.05.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107043","article-title":"Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: a scoping review","volume":"106","author":"Shlobin","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2026.05.013_bib0010","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.yebeh.2004.02.007","article-title":"Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: behavioral risk factor surveillance system, 2002","volume":"5","author":"Kobau","year":"2004","journal-title":"Epilepsy Behav"},{"issue":"19","key":"10.1016\/j.seizure.2026.05.013_bib0011","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.seizure.2026.05.013_bib0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11325-016-1391-3","article-title":"Obstructive sleep apnoea in patients with epilepsy: a meta-analysis","volume":"21","author":"Lin","year":"2017","journal-title":"Sleep Breath"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0013","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.chest.2019.01.016","article-title":"Epilepsy and sleep-related breathing disturbances","volume":"156","author":"Somboon","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.seizure.2026.05.013_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainresbull.2018.06.017","article-title":"The role of the GLP-1\/GLP-1R signaling pathway in regulating seizure susceptibility in rats","volume":"142","author":"Zhang","year":"2018","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11064-022-03736-4","article-title":"The anti-seizure effect of liraglutide on Ptz-induced convulsions through its anti-oxidant and anti-inflammatory properties","volume":"48","author":"Erdogan","year":"2023","journal-title":"Neurochem Res"},{"issue":"5","key":"10.1016\/j.seizure.2026.05.013_bib0016","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/brainsci9050108","article-title":"Effects of GLP-1 receptor activation on a pentylenetetrazole-kindling rat model","volume":"9","author":"Hussein","year":"2019","journal-title":"Brain Sci"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2026.05.013_bib0017","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11010-016-2678-1","article-title":"Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice","volume":"415","author":"Koshal","year":"2016","journal-title":"Mol Cell Biochem"},{"issue":"21","key":"10.1016\/j.seizure.2026.05.013_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110743","article-title":"GLP-1 and the degenerating brain: exploring mechanistic insights and therapeutic potential","volume":"26","author":"Moaket","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seizure.2026.05.013_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176903","article-title":"Targeting microglial GLP1R in epilepsy: a novel approach to modulate neuroinflammation and neuronal apoptosis","volume":"981","author":"Zhang","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2026.05.013_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fphar.2020.00136","article-title":"The glucagon-like peptide-1 analogue liraglutide reduces seizures susceptibility, cognition dysfunction and neuronal apoptosis in a mouse model of dravet syndrome","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.seizure.2026.05.013_bib0021","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3390\/biomedicines12102205","article-title":"Exploring liraglutide in lithium-pilocarpine-induced temporal lobe epilepsy model in rats: impact on inflammation, mitochondrial function, and behavior","volume":"12","author":"Antmen","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.seizure.2026.05.013_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eplepsyres.2018.03.009","article-title":"Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus","volume":"142","author":"Wang","year":"2018","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2019.02.028","article-title":"Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy","volume":"511","author":"Wen","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.seizure.2026.05.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175098","article-title":"Liraglutide chronic treatment prevents development of tolerance to antiseizure effects of diazepam in genetically epilepsy prone rats","volume":"928","author":"De Sarro","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2026.05.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101352","article-title":"Time and metabolic state-dependent effects of GLP-1R agonists on NPY\/AgRP and POMC neuronal activity in vivo","volume":"54","author":"Dong","year":"2021","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.seizure.2026.05.013_bib0026","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/biof.1406","article-title":"Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus","volume":"44","author":"Rebosio","year":"2018","journal-title":"Biofactors"},{"issue":"3","key":"10.1016\/j.seizure.2026.05.013_bib0027","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.seizure.2026.05.013_bib0028","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/epi4.13091","article-title":"Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: a meta-analysis","volume":"9","author":"Sindhu","year":"2024","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.seizure.2026.05.013_bib0029","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3171\/2025.5.JNS25786","article-title":"Impact of GLP-1 receptor agonists on stroke, subarachnoid hemorrhage, and intracerebral hemorrhage: a propensity-matched multi-institutional cohort study","volume":"144","author":"Costa","year":"2026","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214509","article-title":"Association between GLP-1 receptor agonist use and epilepsy risk in type 2 diabetes","volume":"106","author":"Cheng","year":"2026","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.05.013_bib0031","article-title":"Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy","author":"AbuAlrob","year":"2025","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.seizure.2026.05.013_bib0032","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA adverse event reporting system database","volume":"42","author":"Wu","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0033","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-025-67701-9","article-title":"Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases","volume":"17","author":"Kong","year":"2026","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.seizure.2026.05.013_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2025.102474","article-title":"Tirzepatide associated autoimmune encephalitis: a case report","volume":"65","author":"Abdi","year":"2025","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review","volume":"86","author":"Kunutsor","year":"2026","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.seizure.2026.05.013_bib0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.seizure.2026.05.013_bib0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.seizure.2026.05.013_bib0038","series-title":"Default","article-title":"Lamotrigine toxicity associated with GLP-1 agonist initiation: a case series","author":"Alomar","year":"2025"},{"key":"10.1016\/j.seizure.2026.05.013_bib0039","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fendo.2017.00098","article-title":"The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.seizure.2026.05.013_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1410883","article-title":"Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies","volume":"15","author":"Mostafa","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.seizure.2026.05.013_bib0041","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamaneurol.2023.1580","article-title":"Independent associations of incident epilepsy and enzyme-inducing and non-enzyme-inducing antiseizure medications with the development of osteoporosis","volume":"80","author":"Josephson","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0042","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jamaneurol.2024.3976","article-title":"Psychiatric comorbidities in persons with epilepsy compared with persons without epilepsy: a systematic review and meta-analysis","volume":"82","author":"Kwon","year":"2025","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2026.05.013_bib0043","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.013_bib0044","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2024.1803","article-title":"Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA adverse event reporting system database","volume":"68","author":"Lu","year":"2025","journal-title":"Eur Psychiatry"},{"issue":"6","key":"10.1016\/j.seizure.2026.05.013_bib0045","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s11096-025-01943-x","article-title":"Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases","volume":"47","author":"Katranski","year":"2025","journal-title":"Int J Clin Pharm"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:52:10Z","timestamp":1784112730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"alternative-id":["S1059131126001433"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.05.013","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in people with epilepsy: A scoping review of clinical data, safety, and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}